Access Vascular

About

Access Vascular develops and manufactures intravenous catheters and ports from a patented hydrophilic biomaterial (MIMIX), commercializing HydroPICC and HydroMID and pursuing clinical and portfolio expansion.

Mission

Access Vascular manufactures intravenous catheters from a proprietary hydrophilic biomaterial called MIMIX™ that is engineered to mimic the body’s natural chemistry and evade the foreign body response. Its FDA-cleared products include HydroPICC®, HydroPICC® Dual, and HydroMID®, and the MIMIX material is patented. Preclinical and retrospective data presented by the company show a six-fold decrease in complications compared with standard polyurethane catheters, a four-log reduction in bacterial adhesion in an in vitro blood loop model, and a 96% reduction in thrombus accumulation in tested models. The company positions its technology as a way to lower the substantial costs and patient harms associated with vascular access complications. Access Vascular plans to use new funding to ramp production capacity for MIMIX-based devices, to pursue further research into lowering catheter infection rates, and to expand its product portfolio. Leadership frames the technology as poised to transform the standard of care for vascular access. Access Vascular has developed a proprietary hydrophilic, lubricious biomaterial and incorporated it into two commercial venous access devices: the HydroPICC Peripherally Inserted Central Catheter and the HydroMID Midline Catheter. In vitro (and referenced in vivo) studies reported an average 97% reduction in thrombus accumulation on its material versus standard polyurethane catheters. The company was founded in 2015 and is headquartered in Bedford, Mass. Current commercial products are on the market while the company pursues additional clinical and post-market data generation. Planned uses for new capital include generating post-market data on its two devices, expanding its device portfolio, and commercializing that expanded portfolio. The company targets reductions in infection, thrombosis and phlebitis through long-term thrombus-resistant biomaterials. Access Vascular, founded in 2015 by CEO James Biggins, develops intravenous catheters and ports from patented biomaterials that are biocompatible and intended to provide long-term infection protection. Its materials and devices are designed to minimize the risk of bloodstream infection, catheter thrombosis, and vein trauma. The company's first product, the FDA-cleared HydroPICCTM, began commercial use in early 2019. Future applications cited include midlines, dialysis catheters, ports, and other devices. The company intends to expand its portfolio of reduced-thrombosis intravenous devices through continued product development. It plans to use new funding to launch HydroPICC and to initiate its first post-market registry study. Access Vascular is a Bedford, MA–based medical device company developing venous access devices intended to eliminate thrombotic risk. Its lead product, the HydroPICC™, is a peripherally inserted central catheter that has shown in lab testing a reduction in platelet accumulation and therefore thrombosis risk. The company's pipeline includes midlines, a dialysis catheter and ports, all at various stages of development. Access Vascular plans to use the newly raised funds to support submission of a 510(k) application later this year for the HydroPICC. The company raised $3.7M in financing and is led by founder, president and CEO James Biggins. Backers include individual investors and AngelMD, an investment platform and marketplace connecting medical startups, physicians, investors and industry partners.

Quick Facts